olaparib,bevacizumab
roche,astrazeneca,merck
['bevacizumab', 'olaparib', 'ovarian']
provocative data. esmo 2022. overall survival advantage with olaparib +
bevacizumab in the hrd test positive population. continuing to transform the soc in ovarian cance. 
Gyn Oncologist with passion for excellent patient care, clinical trials and drug development. Associate professor @UCSD_OBGYN, views = own